PUBLIC RELEASE DATE:

13-Oct-2014

Contact: Megan Hanks mhanks@acponline.org 215-351-2656 American College of Physicians @ACPinternists

1. Experts urge cautious use of experimental Ebola drugs

While a World Health Organization (WHO) advisory panel says it is ethical to use experimental medications and vaccines on Ebola patients, experts caution that these drugs are not without risks, and physicians must carefully triage patients or risk serious adverse events, according to a commentary being published in Annals of Internal Medicine. The WHO's epidemic-specific conclusion mandates that health care professionals employ particular ethical standards (fairness of dissemination, patient consent, physician nonmaleficence) when using unapproved Ebola drugs. Therein lies the problem, according to the authors. Because the drugs are experimental, physicians will not be able to discern which patients are likely to benefit from treatment. Drug misuse may lead to poorer outcomes for the 'treated' severely ill, missed opportunities for realistically treatable patients, and a possible induction of drug resistance. The authors also suggest that meaningful informed consent may not be possible during this current epidemic. They urge physicians to employ careful triage strategies to maintain principled experimentation. Data and safety monitoring and experimentation protocols with plans for adequate drug supply to allow sufficient research will be required to ensure a better future standard.

Note: Note: The URL for this story will be live at 5:00 p.m. on October 13 and can be used in news stories. For a PDF, please contact Megan Hanks. To interview the lead author, please contact John Easton at john.easton@uchospitals.edu or 773-795-5225.

2. Health economists find major flaw in FDA's tobacco label regulation cost-benefit analysis

The FDA's cost-benefit analysis of its proposed cigarette labeling regulation has a major flaw, according to an Ideas & Opinions piece being published in Annals of Internal Medicine. Federal agencies proposing any significant regulatory action are required to evaluate the regulation's costs and benefits. In this case, the FDA evaluated its proposed rule requiring cigarette packs to bear large graphic warning labels to deter consumers from smoking. Among other components (costs of implementation, FDA administrative and enforcement costs), the FDA included the cost to consumers, or "consumer surplus." The consumer surplus is the pleasure smokers derive from smoking over and above the price they pay for cigarettes. A group of prominent health economists say that including "lost pleasure" from tobacco use as an element of economic impact is flawed thinking because most tobacco users derive little consumer surplus from smoking. Rather they struggle with trying to break an addiction, regret having ever started smoking, and face psychological costs from being addicted and unable to quit. The authors urge the FDA to consider this reality in future economic evaluations of proposed tobacco regulations.

Note: The URL for this story will be live at 5:00 p.m. on October 13 and can be used in news stories. For a PDF or an interview with the lead author, please contact Abby Abazorius at abbya@mit.edu or 617-253-2709.

3. National study is first to report on medical resident knowledge of High Value Care via exam vignettes

Originally posted here:

Tip sheet from Annals of Internal Medicine Oct. 14, 2014